Patients with triple-negative breast cancer (TNBC), who have negative immunohistochemical staining for estrogen receptors (ER), progesterone receptors (PR), and human epidermal growth factor receptor 2 (HER2) [53], have the lowest survival rate and highest mortality within BC patients [54,55]. This evidence concerns the gene ERBB2 and triple-negative breast carcinoma.